SYDNEY and NEW YORK, Sept. 3, 2026 /PRNewswire/ — Mineral exploration company NT1 Pty Ltd (“NT1”), has entered into an Agreement and Plan of Merger and Business Combination Agreement (“BCA”) with Plutonian Acquisition Corp. II (“Plutonian II”), a publicly traded special purpose acquisition company. Upon completion, the transaction contemplated under the BCA will result in a combined company listed on the New York Stock Exchange.

The transaction is expected to close in 2027, subject to regulatory approvals, shareholder approvals, and customary closing conditions. The terms of the transaction provide for NT1 shareholders to receive shares of the Purchaser (a Cayman Islands exempted company to be incorporated as part of the transaction) in exchange for all outstanding NT1 shares, with Purchaser shares valued at USD $10.00 per share for purposes of the exchange consideration. The terms of the transaction represent an estimated enterprise value of NT1 of USD $500 million.

NT1 is an Australian mineral exploration company focused on the acquisition, holding, and exploration of mineral properties and related assets in the West Arunta region of Western Australia and the Northern Territory, with a particular emphasis on rare earth elements, niobium, and IOCG mineral systems.

Following the transaction, NT1 intends to accelerate its growth strategy by expanding exploration activities, strengthening its portfolio of mineral assets, and leveraging its position in the critical minerals sector. The combination with Plutonian II provides NT1 with access to U.S. capital markets and a platform to pursue additional financing opportunities.

Frank Jiang, Chief Financial Officer of NT1, remarked: “This transaction represents a defining moment for NT1. By joining forces with Plutonian II, we unlock new pathways to capital and broaden our global reach. Worldwide demand for rare earths and strategic minerals continues to rise. We believe NT1 is uniquely placed to deliver sustainable growth and contribute meaningfully to international supply chains.”

Wei Kwang NG, Chief Executive Officer of Plutonian II commented: “We are pleased to enter into a definitive business combination agreement with NT1 Resources. We believe this transaction will provide NT1 with a strong public-market platform to advance its exploration strategy and pursue long-term value creation, and we look forward to working closely with the NT1 team toward a successful closing.”

Plutonian Acquisition Corp. II is a Cayman Islands exempted company formed for the purpose of entering into a share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination. As part of the transaction, NT1 will retain its current management team and business structure.

About NT1

NT1 Pty Ltd (“NT1”) is an Australian mineral exploration company headquartered in Sydney, Australia, with operations across Western Australia and the Northern Territory. NT1 is focused on the acquisition, holding, and exploration of mineral properties and related assets, with a particular emphasis on rare earth elements, niobium, and IOCG mineral systems.

About Plutonian II

Plutonian II is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities.

Additional Information About the Proposed Transaction and Where to Find It

The proposed transaction will be submitted to shareholders of Plutonian II and NT1 for their consideration. The combined company intends to file a registration statement on Form F-4 (the “Registration Statement”) with the SEC, which will include a proxy statement/prospectus to be distributed to Plutonian II’s shareholders in connection with Plutonian II’s solicitation for proxies for the vote by its shareholders in connection with the proposed transaction and other matters to be described in the Registration Statement, as well as the prospectus relating to the offer of the securities to be issued to NT1 shareholders in connection with the completion of the proposed transaction. After the Registration Statement has been filed and declared effective, a definitive proxy statement/prospectus and other relevant documents will be mailed to Plutonian II’s shareholders as of the record date established for voting on the proposed transaction. Before making any voting or investment decision, Plutonian II’s shareholders and other interested persons are advised to read, once available, the definitive proxy statement/prospectus, as well as other documents filed with the SEC by Plutonian II in connection with the proposed transaction, as these documents will contain important information about Plutonian II, NT1, and the proposed transaction. Shareholders may obtain a copy of the definitive proxy statement/prospectus, once available, as well as other documents filed by Plutonian II with the SEC, without charge, at the SEC’s website located at www.sec.gov.

Participants in Solicitation

Plutonian II, NT1, and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from Plutonian II’s shareholders in connection with the proposed transactions. Information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of Plutonian II’s shareholders in connection with the proposed transactions will be set forth in the proxy statement/prospectus included in the Registration Statement. You can find more information about Plutonian II’s directors and executive officers in Plutonian II’s final prospectus related to its initial public offering dated April 28, 2026, and subsequent SEC reports. Additional information regarding the participants in the proxy solicitation and a description of their direct and indirect interests will be included in the proxy statement/prospectus when it becomes available. Shareholders, potential investors and other interested persons should read the proxy statement/prospectus carefully when it becomes available before making any voting or investment decisions. You may obtain free copies of these documents from the sources indicated above.

Forward-Looking Statements

This communication contains certain forward-looking statements within the meaning of the federal securities laws with respect to a proposed transaction among Plutonian II, NT1 and the other parties thereto. Forward-looking statements include information concerning the parties’ possible or assumed future results of operations, business strategies, competitive position, industry environment, potential growth opportunities, and the effects of regulation, including whether the transaction will generate returns for shareholders. These forward-looking statements are based on the parties’ management’s current expectations, projections, and beliefs, as well as a number of assumptions concerning future events. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this document. These risks, uncertainties, assumptions, and other important factors include, but are not limited to: (a) the occurrence of any event, change, or other circumstances that could give rise to the termination of negotiations and any subsequent definitive agreements with respect to the transaction; (b) the outcome of any legal proceedings that may be instituted against the parties, or others following the announcement of the transaction and any definitive agreements with respect thereto; (c) the inability to complete the transaction due to the failure to obtain the approval of the shareholders of Plutonian II or NT1 or to satisfy other conditions to closing, including the receipt of certain governmental and regulatory approvals; (d) changes to the proposed structure of the transaction that may be required or appropriate as a result of applicable laws or regulations or as a condition to obtaining regulatory approval of the transaction; (e) the ability to meet the applicable stock exchange listing standards following the consummation of the transaction; (f) the risk that the transaction disrupts current plans and operations of the parties or its subsidiaries as a result of the announcement and consummation of the transactions described herein; (g) the effect of the announcement or pendency of the transaction on the parties’ business relationships, operating results, and business generally; (h) the ability to recognize the anticipated benefits of the transaction, which may be affected by, among other things, competition, the ability of the surviving company to grow and manage growth profitably, maintain relationships with customers and suppliers and retain its management and key employees; (i) costs related to the transaction; (j) changes in applicable laws or regulations, including legal or regulatory developments (including, without limitation, accounting considerations) which could result in unforeseen delays in the timing of the transaction; (k) the possibility that the parties may be adversely affected by other economic, business, and/or competitive factors; and (l) other risks and uncertainties indicated from time to time in Plutonian II’s final prospectus related to its initial public offering dated April 28, 2026, including those under “Risk Factors” therein, and other documents filed or to be filed with the SEC by Plutonian II.

Copies are available on the SEC’s website at www.sec.gov. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in documents filed by Plutonian II or the surviving company from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and the parties assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. No party gives any assurance that any party will achieve its expectations. 

No Offer or Solicitation

This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. This communication is not, and under no circumstances is to be construed as, a prospectus, an advertisement or a public offering of the securities described herein in the United States or any other jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, or exemptions therefrom. INVESTMENT IN ANY SECURITIES DESCRIBED HEREIN HAS NOT BEEN APPROVED BY THE SEC OR ANY OTHER REGULATORY AUTHORITY NOR HAS ANY AUTHORITY PASSED UPON OR ENDORSED THE MERITS OF THE OFFERING OR THE ACCURACY OR ADEQUACY OF THE INFORMATION CONTAINED HEREIN. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE. This press release is not, and under no circumstances is to be construed as, a prospectus, an advertisement or a public offering in any jurisdiction.

SHANGHAI, Sept. 3, 2026 /PRNewswire/ — Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that China’s National Medical Products Administration (NMPA) has approved CARDAMYST^® (etripamil) for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. As Everest’s first innovative therapy approved in the cardiovascular field, CARDAMYST further expands the Company’s cardiovascular portfolio. The approval marks another important milestone in the execution of Everest’s commercialization strategy and reinforces the Company’s capability to bring innovative therapies to patients in China.

CARDAMYST (etripamil) nasal spray is a novel, rapid-acting calcium channel blocker administered as needed via a convenient, portable nasal spray. It offers rapid onset of action, favorable tolerability, and the potential for at-home self-administration, enhancing patient accessibility. CARDAMYST is currently the only self-administered treatment for adults with PSVT to rapidly treat episodes. Treatment effects observed as early as five minutes after administration, with nearly two-thirds of patients achieving conversion to sinus rhythm within 30 minutes, reducing the need for emergency medical interventions and filling a critical gap in out-of-hospital, self-administered treatment options for acute symptomatic episodes of PSVT in China.

The approval of CARDAMYST was supported by the global pivotal Phase III RAPID trial and the Phase III JX02002 study in China. Both studies met their primary endpoints. The RAPID trial achieved its primary endpoint with 64% of participants who self-administered etripamil (N=99) converting from supraventricular tachycardia (SVT) to sinus rhythm within 30 minutes compared to 31% on placebo (N=85) (HR = 2.62; p<0.001). The study results were published in The Lancet in 2023.  In the JX02002 study, among participants with PSVT episodes (N=84), a greater number of patients receiving etripamil achieved conversion to sinus rhythm within 30 minutes, compared with placebo (N=84) (hazard ratio [HR] = 3.002; p=0.0005). In December 2025, CARDAMYST was approved by the U.S. Food and Drug Administration (FDA), becoming the first and only self-administered nasal spray in more than 30 years capable of converting paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults.

PSVT is a type of tachyarrhythmia characterized by the sudden onset and termination of episodes of rapid, regular heart rhythm. The heart rate spike is unpredictable and may last several hours. The rapid heart rate often causes disabling severe palpitations, shortness of breath, chest discomfort, dizziness or lightheadedness, and distress, forcing patients to limit their daily activities. There are currently no approved self-administered, fast-acting, non-injectable therapies for acute PSVT, leaving patients with limited treatment options beyond emergency care. Approximately 2.3 to 4 per 1,000 individuals are affected by PSVT, representing an estimated 3 to 6 million patients in China. 

“PSVT episodes are often sudden and unpredictable and can significantly impact patients’ quality of life. The management of acute PSVT episodes in China has long relied primarily on hospital-based emergency care, highlighting the need for an on-demand treatment option that patients can self-administer outside of healthcare settings,” said Professor Changsheng Ma, M.D., Principal Investigator of the Phase III JX02002 study, Director of Cardiology Department at Beijing Anzhen Hospital, and President of the Chinese Society of Cardiology, Chinese Medical Association, “The approval of CARDAMYST addresses a critical unmet need by introducing the first innovative therapy that enables patients to self-administer treatment for acute PSVT episodes in China. Both the global pivotal Phase III RAPID trial and the China Phase III JX02002 study demonstrated its rapid onset, robust efficacy, and favorable safety profile. In the RAPID trial, CARDAMYST achieved a conversion rate of 64% within 30 minutes. Its efficacy in Chinese patients was further confirmed in the JX02002 study, conducted across 48 leading clinical centers in China. CARDAMYST was generally well tolerated, with predominantly mild adverse events, and significantly reduced the need for emergency department visits. We believe this innovative therapy has the potential to transform the treatment paradigm for acute PSVT episodes by enabling timely, patient-initiated treatment, reducing the need for emergency medical intervention, and ultimately improving patients’ quality of life.”

“The approval of CARDAMYST marks an important milestone, introducing the first out-of-hospital, patient-administered treatment option for acute PSVT episodes in China. This innovative therapy has the potential to shift the management of acute PSVT episodes beyond hospital-based emergency care and help ease the burden on healthcare systems. Patients with PSVT often require emergency medical care during episodes, leaving them with the anxiety and uncertainty associated with unpredictable recurrences,” said Mr. Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. “As the only innovative therapy currently available that enables patients to self-administer treatment for PSVT episodes outside of healthcare settings, CARDAMYST offers a new on-demand treatment option. With treatment effects observed as early as five minutes after administration, CARDAMYST enables patients to manage episodes outside of a healthcare setting, giving them greater control over their condition and potentially reshaping the treatment paradigm for PSVT in China. Leveraging our proven commercialization capabilities, we look forward to accelerating the launch of CARDAMYST in China to address the significant unmet needs of patients with PSVT and realize its long-term clinical and societal value.”

CARDAMYST is also in Phase III clinical development for atrial fibrillation with rapid ventricular response (AFib-RVR), with positive Phase II results supporting its advancement. CARDAMYST has the potential to benefit more than 12 million patients in China, including those with PSVT and AFib-RVR.

About CARDAMYST^® (etripamil) Nasal Spray
Etripamil is a novel calcium channel blocker developed by Milestone Pharmaceuticals Inc. (Nasdaq: MIST). It is designed as a rapid-response therapy for episodic cardiovascular conditions. As a self-administered nasal spray, etripamil has the potential to shift treatment from emergency department-based care to a patient-managed setting. In May 2021, JIXING (now CORXEL) and Milestone entered into an exclusive license agreement for the development and commercialization of investigational drug etripamil for PSVT and other cardiovascular indications in Greater China (“Milestone License Agreement”).  

In March 2026, Everest Medicines entered into an asset purchase agreement with CORXEL Pharmaceuticals to acquire the rights to develop, commercialize, and manufacture CARDAMYST in Greater China.

About Everest Medicines
Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative pharmaceutical products that address critical unmet medical needs for patients in global markets. The management team of Everest Medicines has deep expertise and an extensive track record both in China and with leading global pharmaceutical companies.

The Company’s therapeutic areas of focus include autoimmune, ophthalmology, critical care, and CKM (cardiovascular, kidney, and metabolic) diseases. Everest Medicines has developed a fully integrated commercialization platform that combines omnichannel commercial capabilities with end-to-end product lifecycle management. Leveraging its proprietary mRNA platform, the Company is advancing its existing pipeline, including mRNA in vivo CAR-T and mRNA cancer vaccines, while selectively expanding into additional high-value therapeutic areas with blockbuster potential, and accelerating its global expansion. For more information, please visit the Company’s website: www.everestmedicines.com.